24
19
1
49
2
2
2c
1b
1d
18
35
5a
1d
2 29
1d
25
Ronac Mamtani, MD, MSCE
78
5a
David J. Vaughn MD Associate Professor in GU Oncology
7
5f
Department: Medicine
4
1
b
1d
46
Contact information
4d
4
3
3
3
2
4
b
1f
4d
Division of Hematology Oncology
2e Perelman Center for Advanced Medicine
22 10th Floor, South Pavilion
16 Office #10-308
39 3400 Civic Center Blvd
Philadelphia, PA 19147
26
2e Perelman Center for Advanced Medicine
22 10th Floor, South Pavilion
16 Office #10-308
39 3400 Civic Center Blvd
Philadelphia, PA 19147
2c
Office: 2156627606
34 Fax: (215) 349-8551
24
99
34 Fax: (215) 349-8551
24
Email:
ronac.mamtani@uphs.upenn.edu
12
ronac.mamtani@uphs.upenn.edu
13
Education:
21 7 BS c
2b Cornell University, 2002.
21 7 MD 1e (Internal Medicine) c
37 Stony Brook School of Medicine, 2006.
21 7 MS 22 (Clinical Epidemiology) c
34 University of Pennsylvania , 2012.
c
3
3
3
3
8d
Permanent link21 7 BS c
2b Cornell University, 2002.
21 7 MD 1e (Internal Medicine) c
37 Stony Brook School of Medicine, 2006.
21 7 MS 22 (Clinical Epidemiology) c
34 University of Pennsylvania , 2012.
c
2 29
21
1e
1d
24
2b
29
27
23
174 Squires P, Cook EE, Song Y, Wang CY, Zhang A, Seshasayee SM, Rogiers A, Li H, Mamtani R.: Treatment Patterns, Disease Recurrence, and Overall Survival in Patients With Muscle-Invasive Bladder Cancer After Radical Cystectomy: A Population-Level Claims-Based Analysis. Clin Genitourin Cancer Feb 2026.
d6 Chow RD, Sedhom R, Mamtani R.: Reduced-Dose Enfortumab Vedotin, Treatment Continuity, and Survival in Urothelial Cancer. JAMA Oncol Nov 2025.
f7 Litt HK, Mamtani R, Chow RD.: Outcomes of enfortumab vedotin plus pembrolizumab in patients with advanced urothelial cancer and severe renal dysfunction. Urol Oncol Nov 2025.
131 Kong AM, Andrean D, Khan S, Choi J, Mamtani R, Parikh R, Jaksa A, Campbell U.: Considerations for emulations of randomized controlled trials using real-world data: learnings from an emulation of MONALEESA-2. J Comp Eff Res Oct 2025.
10c Chow RD, Mamtani R.: Assessment of synergistic vs. independent drug activity for enfortumab vedotin and pembrolizumab in untreated advanced urothelial carcinoma. Urol Oncol 43(10): 597, Oct 2025.
161 Meng Y, Zhang S, Aout M, Babcock A, Li H, Lai Y, Brand-Wiita S, Notinger S, Bavle A, Mamtani R.: Cost-effectiveness of enfortumab vedotin plus pembrolizumab as a first-line treatment of locally advanced or metastatic urothelial carcinoma in the United States. J Med Econ Oct 2025.
15a Squires P, Cook EE, Song Y, Wang CY, Jiang AX, Zhang A, Seshasayee SM, Rogiers A, Li H, Mamtani R.: Real-world economic burden of disease recurrence in patients with muscle-invasive bladder cancer: A population-level claims-based analysis. J Manag Care Spec Pharm Sep 2025.
10b Chow RD, Mamtani R.: Association Between Early on-Treatment Weight Loss With Enfortumab Vedotin Plus Pembrolizumab and Survival in Advanced Urothelial Carcinoma. Clin Genitourin Cancer Aug 2025.
111 Parikh RB, Ulloa-Pérez E, Kurian M, Hubbard R, Joffe S, Lynch HF, Mamtani R.: Prescribing Changes After Accelerated vs Regular Approval of Oncology Therapies. JAMA Netw Open 8(7): e2520726, Jul 2025.
2c
7
1d
1f
Selected Publications
1bb Litt HK, Wodzinski A, Subramanian P, Donovan M, Vapiwala N, Parikh RB, Narayan V, Mei L, Takvorian SU, Balzer Haas N, Mistry R, and Mamtani R.: OncoEducate: A pilot study of generative AI to support patient education in GU cancer care. American Society of Clinical Oncology Genitourinary Cancers Symposium, San Fran, CA. 44(7): 713, Mar 2026 Notes: "Poster Presentation"174 Squires P, Cook EE, Song Y, Wang CY, Zhang A, Seshasayee SM, Rogiers A, Li H, Mamtani R.: Treatment Patterns, Disease Recurrence, and Overall Survival in Patients With Muscle-Invasive Bladder Cancer After Radical Cystectomy: A Population-Level Claims-Based Analysis. Clin Genitourin Cancer Feb 2026.
d6 Chow RD, Sedhom R, Mamtani R.: Reduced-Dose Enfortumab Vedotin, Treatment Continuity, and Survival in Urothelial Cancer. JAMA Oncol Nov 2025.
f7 Litt HK, Mamtani R, Chow RD.: Outcomes of enfortumab vedotin plus pembrolizumab in patients with advanced urothelial cancer and severe renal dysfunction. Urol Oncol Nov 2025.
131 Kong AM, Andrean D, Khan S, Choi J, Mamtani R, Parikh R, Jaksa A, Campbell U.: Considerations for emulations of randomized controlled trials using real-world data: learnings from an emulation of MONALEESA-2. J Comp Eff Res Oct 2025.
10c Chow RD, Mamtani R.: Assessment of synergistic vs. independent drug activity for enfortumab vedotin and pembrolizumab in untreated advanced urothelial carcinoma. Urol Oncol 43(10): 597, Oct 2025.
161 Meng Y, Zhang S, Aout M, Babcock A, Li H, Lai Y, Brand-Wiita S, Notinger S, Bavle A, Mamtani R.: Cost-effectiveness of enfortumab vedotin plus pembrolizumab as a first-line treatment of locally advanced or metastatic urothelial carcinoma in the United States. J Med Econ Oct 2025.
15a Squires P, Cook EE, Song Y, Wang CY, Jiang AX, Zhang A, Seshasayee SM, Rogiers A, Li H, Mamtani R.: Real-world economic burden of disease recurrence in patients with muscle-invasive bladder cancer: A population-level claims-based analysis. J Manag Care Spec Pharm Sep 2025.
10b Chow RD, Mamtani R.: Association Between Early on-Treatment Weight Loss With Enfortumab Vedotin Plus Pembrolizumab and Survival in Advanced Urothelial Carcinoma. Clin Genitourin Cancer Aug 2025.
111 Parikh RB, Ulloa-Pérez E, Kurian M, Hubbard R, Joffe S, Lynch HF, Mamtani R.: Prescribing Changes After Accelerated vs Regular Approval of Oncology Therapies. JAMA Netw Open 8(7): e2520726, Jul 2025.
2c
44
23
Back to Top
1b
1d
18